This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:mp [10.16.2017] – [Stopping olmesartan] sallieq | home:mp [06.11.2018] – [Background and scientific rationale for the therapy] sallieq | ||
---|---|---|---|
Line 28: | Line 28: | ||
===== Background and scientific rationale for the therapy ===== | ===== Background and scientific rationale for the therapy ===== | ||
- | < | + | < |
+ | * [[home: | ||
+ | * [[home: | ||
+ | * [[home: | ||
+ | * [[home: | ||
+ | </ | ||
Line 212: | Line 217: | ||
ARF has prepared a [[home: | ARF has prepared a [[home: | ||
* **Do not withdraw olmesartan** – In a critical care situation, it is essential to continue oral olmesartan, even in the presence of hypotension, | * **Do not withdraw olmesartan** – In a critical care situation, it is essential to continue oral olmesartan, even in the presence of hypotension, | ||
- | * **antibiotics** – We strongly recommend patients not be treated with MP antibiotics for an acute infection. Unless patients have reached a late stage of the treatment these antibiotics may greatly increase immunopathology as they leave a patient' | + | * **antibiotics** – We strongly recommend patients not be treated with MP antibiotics for an acute infection. Unless patients have reached a late stage of the treatment these antibiotics may greatly increase immunopathology as they leave a patient' |
* **corticosteroids** – Do not give corticosteroids in any form or by any route (injected, inhaled, oral or IV) as they will lead to metabolic instability. | * **corticosteroids** – Do not give corticosteroids in any form or by any route (injected, inhaled, oral or IV) as they will lead to metabolic instability. | ||
* Do not give **nimesulide** (Aulin / Mesulid / Nimed). | * Do not give **nimesulide** (Aulin / Mesulid / Nimed). |